A point-of-care ultrasound-driven diagnostic pathway for emergency department patients with dyspnoea: a randomised controlled trial
Abstract
Background: Previous trials have suggested that point-of-care ultrasound (POCUS) for emergency department (ED) patients with dyspnoea increases the proportion of patients discharged within 24 h. We aimed to assess whether this effect could be confirmed.
Methods: This trial was a randomised controlled trial in 10 Danish EDs. Adult patients presenting to the ED with dyspnoea as chief complaint were randomised to the addition or omission of focused lung and cardiac ultrasound. The primary outcome was the proportion of patients discharged alive within 24 h. Secondary outcomes included overall hospital length of stay, chest imaging utilisation, and 72 h alive and revisit-free.
Results: Among 674 patients who were randomised between 25 January 2023 and 23 August 2024, 663 were included in the analysis. The primary outcome occurred in 141 (42.6%) out of 331 patients in the intervention group versus 151 (45.5%) out of 332 in the control group (risk difference -2.9, 95% CI -10.4-4.7; p=0.45). The overall incidence rate of hospital discharges per person-days at risk was 0.28 in the intervention group versus 0.32 in the control group (hazard ratio 0.93, 95% CI 0.79-1.08; p=0.35).
Conclusions: In adult ED patients with dyspnoea as chief complaint, a POCUS-driven diagnostic pathway did not alter the proportion of patients discharged alive within 24 h or the overall hospital length of stay compared with standard care.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 674 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.